New insights into the pharmacodynamic and pharmacokinetic properties of statins. Brown, M. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. Lipid Res. Goldstein, J. Protein sensors for membrane sterols.
Cell , 35—46 Song, B. Insig-mediated degradation of HMG CoA reductase stimulated by lanosterol, an intermediate in the synthesis of cholesterol. Cell Metab. DeBose-Boyd, R. Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and degradation of HMG CoA reductase.
Cell Res. Sever, N. Insig-dependent ubiquitination and degradation of mammalian 3-hydroxymethylglutaryl-CoA reductase stimulated by sterols and geranylgeraniol. Induction of 3-hydroxymethylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin MLB , a competitive inhibitor of the reductase.
Lee, P. Isolation of sterol-resistant Chinese hamster ovary cells with genetic deficiencies in both Insig-1 and Insig Orci, L. Increase in membrane cholesterol: a possible trigger for degradation of HMG CoA reductase and crystalloid endoplasmic reticulum in UT-1 cells.
Cell 36 , — Kita, T. Feedback regulation of 3-hydroxymethylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. Schonewille, M. Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice. Hwang, S. Contribution of accelerated degradation to feedback regulation of 3-hydroxymethylglutaryl coenzyme A reductase and cholesterol metabolism in the liver.
Ness, G. Bilhartz, L. Inappropriate hepatic cholesterol synthesis expands the cellular pool of sterol available for recruitment by bile acids in the rat. Burnett, J. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxymethylglutaryl coenzyme A reductase inhibition in miniature pigs. Endocrinology , — Reihner, E. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
Preiss, D. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA , — Maki, K. Rosenson, R. Armitage, J. The safety of statins in clinical practice. Buettner, C. Statin use and musculoskeletal pain among adults with and without arthritis. Pineda, A. Statin rebound or withdrawal syndrome: does it exist? Daskalopoulou, S. When statin therapy stops: implications for the patient. Liscum, L. Domain structure of 3-hydroxymethylglutaryl coenzyme A reductase, a glycoprotein of the endoplasmic reticulum.
Roitelman, J. Immunological evidence for eight spans in the membrane domain of 3-hydroxymethylglutaryl coenzyme A reductase: implications for enzyme degradation in the endoplasmic reticulum. Cell Biol. Accelerated degradation of HMG CoA reductase mediated by binding of insig-1 to its sterol-sensing domain. Cell 11 , 25—33 Gp78, a membrane-anchored ubiquitin ligase, associates with Insig-1 and couples sterol-regulated ubiquitination to degradation of HMG CoA reductase. Cell 19 , — Cao, J.
Ufd1 is a cofactor of gp78 and plays a key role in cholesterol metabolism by regulating the stability of HMG-CoA reductase.
Jiang, L. Ravid, T. The ubiquitin-proteasome pathway mediates the regulated degradation of mammalian 3-hydroxymethylglutaryl-coenzyme A reductase. Jo, Y. Lai, A. Induced protein degradation: an emerging drug discovery paradigm. Suppression of 3-hydroxymethylglutaryl coenzyme A reductase activity and inhibition of growth of human fibroblasts by 7-ketocholesterol.
Bell, J. Inhibition of 3-hydroxymethylglutaryl coenzyme A reductase activity in hepatoma tissue culture cells by pure cholesterol and several cholesterol derivatives. Evidence supporting two distinct mechanisms. Kandutsch, A. Regulation of sterol synthesis in cultured cells by oxygenated derivatives of cholesterol.
Cell Physiol. Lange, Y. Effectors of rapid homeostatic responses of endoplasmic reticulum cholesterol and 3-hydroxymethylglutaryl-CoA reductase. Nguyen, A. Hypoxia stimulates degradation of 3-hydroxymethylglutaryl-coenzyme A reductase through accumulation of lanosterol and hypoxia-inducible factor-mediated induction of insigs. Repa, J.
Genes Dev. Natl Acad. USA 98 , — Sharpe, L. USA , — Pencina, M. Application of new cholesterol guidelines to a population-based sample. Lloyd-Jones, D. Statins, risk assessment, and the new American prevention guidelines.
Stone, N. Min, H. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Ioannou, G. The role of cholesterol in the pathogenesis of NASH. Trends Endocrinol. Dongiovanni, P. Statin use and non-alcoholic steatohepatitis in at risk individuals.
Mullen, P. The interplay between cell signalling and the mevalonate pathway in cancer. Cancer 16 , — Zipp, F. Trends Pharmacol. McCarthy, C. Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis. Xia, Y. The mevalonate pathway is a druggable target for vaccine adjuvant discovery. Cell , Ubiquitination of 3-hydroxymethylglutaryl-CoA reductase in permeabilized cells mediated by cytosolic E1 and a putative membrane-bound ubiquitin ligase.
Fermini, B. The impact of drug-induced QT interval prolongation on drug discovery and development. Sanguinetti, M. Nature , — Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol. Hannah, V. Unsaturated fatty acids down-regulate srebp isoforms 1a and 1c by two mechanisms in HEK cells. Li, P. The clathrin adaptor Numb regulates intestinal cholesterol absorption through dynamic interaction with NPC1L1. Tang, J. Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques.
Download references. We thank Y. You can also search for this author in PubMed Google Scholar. Reprints and Permissions. Jiang, SY. Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol. Nat Commun 9, Download citation. Received : 12 July Accepted : 31 October Published : 03 December Anyone you share the following link with will be able to read this content:.
Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. Chinese Medicine Scientific Reports Nature Communications By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
Advanced search. Skip to main content Thank you for visiting nature. Download PDF. Subjects Dyslipidaemias Sterols Ubiquitylated proteins. Abstract Statins are inhibitors of HMG-CoA reductase, the rate-limiting enzyme of cholesterol biosynthesis, and have been clinically used to treat cardiovascular disease.
Full size image. Discussion Statins are the most prescribed drug regimen for treating CVDs since they were first introduced to the market in the late s. Serum and liver chemistry Mice were anesthetized and blood collection was performed. Statistical analyses All statistical analyses were performed using the GraphPad Prism 6 software.
Chemical synthesis and characterization The synthesis procedure and spectra characterization of compounds used in this study are described in the Supplementary Figs. Reporting summary Further information on research design is available in the Nature Research Reporting Summary linked to this article. Data availability The data that support the findings of this study are available within the paper and its supplementary information files, and from the corresponding author upon reasonable request.
References 1. Article Google Scholar 2. Article Google Scholar 4. Google Scholar 6. Article Google Scholar 7. Article Google Scholar 8. Article Google Scholar Acknowledgements We thank Y. View author publications. Ethics declarations Competing interests The authors declare no competing interests. Electronic supplementary material. Supplementary Information. Peer Review File. Description of Additional Supplementary Files. Supplementary Data 1. Reporting Summary.
About this article. Cite this article Jiang, SY. Copy to clipboard. Thompson , Richard G. Lee , Gary W. Cline , Jeffrey G. Some have even had success with once-weekly dosing of rosuvastatin. References: Stone NJ, et al. J Am Coll Cardiol. Back to Healio. Topic Reviews A-Z Save. Side Effects Myalgias are common with statin therapy. Read more about cholesterol. Related Content. Please refresh your browser and try again. If this error persists, please contact ITSupport wyanokegroup.
Removed from market due to rhabdomyolysis risk. Low potency Few drug interactions. Low to moderate potency Metabolized in CYP3A4; high drug interaction risk Significantly raises cyclosporine levels in transplant patients.
0コメント